David Fontana, Ph.D., has become chief business and strategy officer of Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies.
Healthcare and molecular diagnostics veteran and former Abbott executive Mark Szewczyk has become chief commercial officer of Strata Oncology Inc., a precision oncology company advancing molecular indications for cancer therapies.
Tavanta Therapeutics, a specialty pharmaceutical company, has several new additions to its executive and senior leadership teams with the appointment of Andreas Maetzel, M.D., PhD as chief medical officer and the promotion of Elizabeth Manning Duus, Ph.D. to VP of clinical development.
Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers, picked Philip Kantoff, M.D., as CEO.
Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP platform technology, appointed Jan Thirkettle, Ph.D. as CEO.
Viracta Therapeutics Inc., a precision oncology company targeting virus-associated malignancies, appointed Ayman El-Guindy, Ph.D., as chief scientific officer.
Travecta Therapeutics appointed Charles S. Ryan, J.D., Ph.D., as president and CEO.
Richard Morris has become chief financial officer for Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.
Amphista Therapeutics, a biopharmaceutical company developing oncology drugs through its targeted protein degradation technology, added Martin O’Rourke as head of drug discovery and James Osborne as director of chemistry.
Malene Jensen has become VP clinical development at Medivir AB. She assumes the role after the summer, at the latest October 1, 2021. She will also join the company’s executive team.
